表紙
市場調查報告書
商品編碼
1029824

全球免疫抑制劑市場(2021-2028)

Global Immunosuppressants Drugs Market - 2021-2028

出版日期: | 出版商: DataM Intelligence | 英文 180 Pages | 商品交期: 約2個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

  • 全貌
  • 簡介
  • 目錄
簡介

器官移植手術的創新和進步推動了全球免疫抑製藥物市場的增長。這些手術數量的增加預計將在預測期內推動市場增長。然而,器官捐獻者的短缺和免疫抑製藥物的高成本預計將在預測期內阻礙市場增長。

此外,由於自身免疫性疾病的患病率不斷上升和器官移植數量的快速增加,預計北美地區在市場上將佔據全球市場的很大份額。此外,組織工程和器官移植方面的技術進步、醫療成本和研發投資的增加,以及成熟的醫療基礎設施的存在,極大地促進了該地區整體市場的增長。

本報告調查了全球免疫抑制劑市場,包括市場規模、機會和影響、增長和抑制因素、COVID-19 影響、藥物類別、適應症、分銷渠道和區域市場。它提供了分析、競爭條件、和主要公司的簡介。

目錄

第 1 章全球免疫抑制劑市場的研究方法和範圍

  • 調查方法
  • 調查的目的和範圍

第 2 章全球免疫抑制劑市場-市場定義和概述

第 3 章全球免疫抑制劑市場-執行摘要

  • 按藥物類別劃分的市場細分
  • 按適應症細分的市場
  • 按分銷渠道劃分的市場細分
  • 按地區劃分的市場細分

第 4 章全球免疫抑制劑市場-市場動態

  • 影響市場的因素
    • 增長因素
    • 抑制因素
    • 市場機會
    • 影響分析

第 5 章全球免疫抑制劑市場-行業分析

  • 波特五力分析
  • 供應鏈分析
  • 價格分析
  • 監管分析
  • 贖回分析
  • 未滿足的需求

第 6 章全球免疫抑制劑市場-COVID-19 分析

  • 市場上的 COVID-19 分析
    • COVID-19 之前的市場情景
    • 當前市場情景
    • COVID-19 或更高版本或未來情況
  • COVID-19 的價格趨勢
  • 供需範圍
  • 大流行期間與市場相關的政府舉措
  • 製造商的戰略計劃
  • 結論

第 7 章全球免疫抑制劑市場-按藥物類別

  • 簡介
    • 市場規模分析及同比增長分析
    • 市場吸引力指數
  • 鈣調神經磷酸□抑制劑
  • 抗增殖劑
  • mTOR 抑制劑
  • 類固醇
  • 其他

第 8 章全球免疫抑制劑市場-適應症

  • 簡介
    • 市場規模分析及同比增長分析
    • 市場吸引力指數
  • 器官移植
  • 自身免疫性疾病
  • 非自身免疫性炎症性疾病

第 9 章全球免疫抑制劑市場-按分銷渠道

  • 簡介
    • 市場規模分析及同比增長分析
    • 市場吸引力指數
  • 醫院藥房
  • 藥房
  • 其他

第 10 章全球免疫抑制劑市場-按地區

  • 簡介
    • 市場規模分析(2018-2028)及同比增長分析(2020-2028)
    • 市場吸引力指數
  • 北美
    • 簡介
    • 主要地區機械師
    • 按藥物類別:市場規模分析和同比增長分析
    • 按適應症:市場規模分析和同比增長分析
    • 按分銷渠道:市場規模分析和同比增長分析
    • 按國家/地區:市場規模分析和同比增長分析
  • 歐洲
    • 簡介
    • 主要地區機械師
    • 按藥物類別:市場規模分析和同比增長分析
    • 按適應症:市場規模分析和同比增長分析
    • 按分銷渠道:市場規模分析和同比增長分析
    • 按國家/地區:市場規模分析和同比增長分析
  • 南美洲
    • 簡介
    • 主要地區機械師
    • 按藥物類別:市場規模分析和同比增長分析
    • 按適應症:市場規模分析和同比增長分析
    • 按分銷渠道:市場規模分析和同比增長分析
    • 按國家/地區:市場規模分析和同比增長分析
  • 亞太地區
    • 簡介
    • 主要地區機械師
    • 按藥物類別:市場規模分析和同比增長分析
    • 按適應症:市場規模分析和同比增長分析
    • 按分銷渠道:市場規模分析和同比增長分析
    • 按國家/地區:市場規模分析和同比增長分析
  • 中東和非洲
    • 簡介
    • 主要地區機械師
    • 按藥物類別:市場規模分析和同比增長分析
    • 按適應症:市場規模分析和同比增長分析
    • 按分銷渠道:市場規模分析和同比增長分析

第 11 章全球免疫抑制劑市場-競爭形勢

  • 主要發展和戰略
  • 公司股票分析
  • 產品基準
  • 值得關注的大公司名單
  • 擁有顛覆性技術的公司
  • 初創公司名單

第 12 章全球免疫抑制劑市場公司概況概述

  • Pfizer Inc
    • 公司簡介
    • 產品組合/概覽
    • 要點
    • 財務概覽
  • Astellas Pharma, Inc
  • Sanofi(Genzyme)
  • Bristol-Myers Squibb Company
  • Novartis AG
  • F. Hoffmann-La Roche Ltd
  • GlaxoSmithKline Plc
  • Allergan Plc
  • Accord Healthcare Ltd
  • Mylan Laboratories, Inc

第 13 章全球免疫抑制劑市場-DataM

  • 附錄
  • 關於我們的公司和服務
  • 聯繫我們
目錄
Product Code: DMPH4059

Market Overview

The global immunosuppressants drugs size was worth US$ XX billion in 2018 and is estimated to reach US$ XX billion by 2028, growing at a CAGR of XX % during the forecast period (2021-2028).

Immunosuppressant drugs are a class of drugs that suppress, or reduce, the strength of the body's immune system. During organ transplantation, from a donor to a recipient, immune system of the recipient gets stimulated and thus, produces immune response like it does in response to other foreign material. This immune response causes serious damage to the transplanted or grafted organ. It is often called as rejection, which can be acute or chronic. This organ rejection is prohibited by using immunosuppressive drugs, which block the immune response and protect new organ and its function.

Market Dynamics

The global immunosuppressants drugs market growth is driven by innovations and advancements in organ transplantation procedures. The rise in volume of these procedures is driving the growth of the market in the forecast period.

The increasing prevalence of diabetes, is expected to drive the growth in the forecast period

An immunosuppressant is an agent that can suppress or prevent the immune response. Immunosuppressants drugs are used to prevent rejection of a transplanted organ and to treat autoimmune diseases such as type 1 diabetes, rheumatoid arthritis, psoriasis/psoriatic arthritis, multiple sclerosis, systemic lupus erythematosus (SLE), inflammatory bowel disease, Addison's disease, and graves' disease among others. Commonly used immunosuppressants drugs include tacrolimus, cyclosporine A, glucocorticoids, methotrexate, and rituximab.

According to the 2017 report of the International Diabetes Federation (IDF), approximately 425 million adults (20-79 years) were suffering from diabetes, and by 2045 this number may rise to 629 million, globally. Several government organizations and NGOs are working to increase awareness about the socioeconomic impact of autoimmunity through fostering and facilitating collaboration in the areas of education, public awareness, research, and patient services in an effective, ethical, and efficient manner. These factor will drive the growth of the market in the forecast period.

Increasing prevalence of autoimmune diseases,expected to drive the market growth

Increasing prevalence of autoimmune diseases, rising cases of organ failure and the requirement of organ transplantation and technological advancements in tissue engineering and organ transplantations are the key driving factors in the immunosuppressant drugs market. For instance, according to the U.S. National Kidney Association, 17,107 kidney transplants took place in the US. In addition, as per the U.S. Government Information on Organ Donation and Transplantation, 36,528 organ transplants were performed in 2018 in the country. For instance, as per the U.S. Government Information on Organ Donation and Transplantation, more than 113,000 number of individuals are on the national transplant waiting list as of July 2019. On the contrary, increase in use of tissue engineering for generation of implants provide growth opportunities for the market. In addition, rise in disposable income in developing economies and surge in awareness among individuals toward organ donation is anticipated to create lucrative opportunities for the market in the near future.

Dearth of availability of organ donors is likely to hinder the market growth

However, dearth of availability of organ donors and high cost of these drugs will hamper the growth of the market in the forecast period.

COVID-19 Impact Analysis

About 23.5 million Americans live with an autoimmune disease. Immunosuppression may increase the risk of developing COVID-19 or having a more severe cases. There are instances in which having an autoimmune disease increases vulnerability to COVID-19 complications, and other cases in which having a coronavirus infection may trigger autoimmune disease cases. This factor will hamper the market growth during the pendamic.

Segment Analysis

Calcineurin inhibitors segment is expected to grow at the fastest CAGR during the forecast period (2021-2028)

Calcineurin Inhibitors segment holds a significant market share in the immunosuppressant drugs market due to its wide applications including utilization in organ transplant recipients and also for the treatment of autoimmune diseases. Calcineurin inhibitors are medicines that inhibit the action of calcineurin which is an enzyme that activates T-cells of the immune system. These inhibitors exert their effects by reducing interleukin-2 production and receptor expression, leading to a reduction in T-cell activation.

According to the U.S. Department of Health and Human Services and Health Resources and Services Administration, more than 113,000 people were in need of transplants as of 2019 and 36,528 transplants were performed in the year 2018. Increasing the prevalence of autoimmune diseases and the rapid rise in the number of organ transplants are the key driving factors in the calcineurin inhibitors segment. According to the National Institute of Environmental Health Sciences, autoimmune diseases affect more than 24 million people in the United States. In addition, eight million people have blood molecules, auto-antibodies that indicate a person's chance of developing an autoimmune disease. These factors are driving the growth of the market in the forecast period.

The hospital pharmacy are expected to dominate the immunosuppressants drugs market during the forecast period

The hospital pharmacy held the largest share in the immunosuppressants drugs market. This is mainly owing to increasing number of patients suffering from conditions which are treated in hospitals equipped with advanced infrastructure and adequate facilities. Moreover, growing number of hospitals along with adequate reimbursement policies is contributing to the growth of this segment.

Geographical Analysis

North America region holds the largest market share global immunosuppressants drugs market

North America is expected to hold a major market share in the global immunosuppressant drugs market due to the increasing prevalence of autoimmune diseases and the rapid rise in the number of organ transplants in this region. According to the Centers for Disease Control (CDC), in the year 2017, it was estimated that approximately 19 percent of men and 25 percent of women in the United States had doctor-diagnosed arthritis, in addition, doctor-diagnosed arthritis was prevalent in 16.4 percent of people who were underweight, while 27.7 percent of individuals who were obese. Furthermore, technological advancements in tissue engineering and organ transplantations, increasing healthcare spending coupled with increasing investments in the research and development and presence of well-established healthcare infrastructure is also fueling the growth of the overall regional market to a large extent. Drug classes such as CETP inhibitors have been withdrawn or discontinued even in the later stages of trials due to adverse effects or failure to achieve satisfactory results. Risks associated with immunosuppressants pose a major challenge to their entry into the market.

Competitive Landscape

The immunosuppressants drugs market is moderately competitive with presence of local as well as global companies. Some of the key players which are contributing to the growth of the market include Astellas Pharma, Inc, Sanofi (Genzyme), Bristol-Myers Squibb Company, Novartis AG, F. Hoffmann-La Roche Ltd, Pfizer Inc, GlaxoSmithKline Plc, Allergan Plc, Accord Healthcare Ltd and Mylan Laboratories, Inc. among others. The major players are adopting several growth strategies such as product launches, acquisitions, and collaborations, which are contributing to the growth of the immunosuppressants drugs market globally.

Pfizer Inc

  • Overview: Pfizer Inc. (Pfizer), incorporated on June 2, 1942, is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines. The Company sold its products in over 125 countries.
  • Product Portfolio: The Company's portfolio comprised of include internal medicine, vaccines, oncology, inflammation and immunology and rare diseases and others.

Why Purchase the Report?

  • Visualize the composition of the immunosuppressants drugs market segmentation by drug class, indication, distribution channel, and region highlighting the key commercial assets and players.
  • Identify commercial opportunities in immunosuppressants drugs market by analyzing trends and co-development deals.
  • Excel data sheet with thousands of data points of immunosuppressants Drugs market - level 4/5 segmentation.
  • PDF report with the most relevant analysis cogently put together after exhaustive qualitative interviews and in-depth market study.
  • Product mapping in excel for the key product of all major market players

The global immunosuppressants drugs market report would provide an access to an approx. 45+ market data table, 40+ figures and 180 pages.

Target Audience

  • Service Providers/ Buyers
  • Industry Investors/Investment Bankers
  • Education & Research Institutes
  • Research Professionals
  • Emerging Companies
  • Manufacturers

Market Segmentation

Global Immunosuppressants Drugs Market - By Drug Class

  • Calcineurin Inhibitors
  • Antiproliferative Agents
  • mTOR Inhibitor
  • Steroids
  • Other

Global Immunosuppressants Drugs Market- By Indication

  • Organ Transplantation
  • Autoimmune Disorders
  • Non-Autoimmune Inflammatory Diseases

Global Immunosuppressants Drugs Market - By Distribution Channel

  • Hospital Pharmacy
  • Pharmacy Stores
  • Other

Global Immunosuppressants Drugs Market - By Region

  • North America
  • South America
  • Europe
  • Asia Pacific
  • Middle East & Africa

Table of Contents

1. Global Immunosuppressants Drugs Market Methodology and Scope

  • 1.1. Research Methodology
  • 1.2. Research Objective and Scope of the Report

2. Global Immunosuppressants Drugs Market - Market Definition and Overview

3. Global Immunosuppressants Drugs Market - Executive Summary

  • 3.1. Market Snippet by Drug Class
  • 3.2. Market snippet by Indication
  • 3.3. Market Snippet by Distribution Channel
  • 3.4. Market Snippet by Region

4. Global Immunosuppressants Drugs Market - Market Dynamics

  • 4.1. Market Impacting Factors
    • 4.1.1. Drivers
      • 4.1.1.1. Growing Prevalence of Autoimmune Diseases and Rise in the Number of Organ Transplants
      • 4.1.1.2. Technological Advancements in Tissue Engineering and Organ Transplantations
    • 4.1.2. Restraints:
      • 4.1.2.1. Stringent Regulatory Processes
    • 4.1.3. Opportunity
    • 4.1.4. Impact Analysis

5. Global Immunosuppressants Drugs Market - Industry Analysis

  • 5.1. Porter's Five Forces Analysis
  • 5.2. Supply Chain Analysis
  • 5.3. Pricing Analysis
  • 5.4. Regulatory Analysis
  • 5.5. Reimbursement Analysis
  • 5.6. Unmet Needs

6. Global Immunosuppressants Drugs Market - COVID-19 Analysis

  • 6.1. Analysis of Covid-19 on the Market
    • 6.1.1. Before COVID-19 Market Scenario
    • 6.1.2. Present COVID-19 Market Scenario
    • 6.1.3. After COVID-19 or Future Scenario
  • 6.2. Pricing Dynamics Amid Covid-19
  • 6.3. Demand-Supply Spectrum
  • 6.4. Government Initiatives Related to the Market During Pandemic
  • 6.5. Manufacturers Strategic Initiatives
  • 6.6. Conclusion

7. Global Immunosuppressants Drugs Market - By Drug Class

  • 7.1. Introduction
    • 7.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class Segment
    • 7.1.2. Market Attractiveness Index, By Drug Class Segment
  • 7.2. Calcineurin Inhibitors*
    • 7.2.1. Introduction
    • 7.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 7.3. Antiproliferative Agents
  • 7.4. mTOR Inhibitor
  • 7.5. Steroids
  • 7.6. Other

8. Global Immunosuppressants Drugs Market - By Indication

  • 8.1. Introduction
    • 8.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 8.1.2. Market Attractiveness Index, By Indication
  • 8.2. Organ Transplantation *
    • 8.2.1. Introduction
    • 8.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 8.3. Autoimmune Disorders
  • 8.4. Non-Autoimmune Inflammatory Diseases

9. Global Immunosuppressants Drugs Market - By Distribution Channel

  • 9.1. Introduction
    • 9.1.1. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel Segment
    • 9.1.2. Market Attractiveness Index, By Distribution Channel Segment
  • 9.2. Hospital Pharmacy *
    • 9.2.1. Introduction
    • 9.2.2. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028
  • 9.3. Pharmacy Stores
  • 9.4. Other

10. Global Immunosuppressants Drugs Market - By Region

  • 10.1. Introduction
    • 10.1.1. Market Size Analysis, US$ Million, 2018-2028 and Y-o-Y Growth Analysis (%), 2020-2028, By Region
    • 10.1.2. Market Attractiveness Index, By Region
  • 10.2. North America
    • 10.2.1. Introduction
    • 10.2.2. Key Region-Specific Dynamics
    • 10.2.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.2.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 10.2.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.2.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.2.6.1. U.S.
      • 10.2.6.2. Canada
      • 10.2.6.3. Mexico
  • 10.3. Europe
    • 10.3.1. Introduction
    • 10.3.2. Key Region-Specific Dynamics
    • 10.3.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.3.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 10.3.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.3.6.
    • 10.3.7. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.3.7.1. Germany
      • 10.3.7.2. U.K.
      • 10.3.7.3. France
      • 10.3.7.4. Italy
      • 10.3.7.5. Spain
      • 10.3.7.6. Rest of Europe
  • 10.4. South America
    • 10.4.1. Introduction
    • 10.4.2. Key Region-Specific Dynamics
    • 10.4.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.4.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 10.4.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.4.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.4.6.1. Brazil
      • 10.4.6.2. Argentina
      • 10.4.6.3. Rest of South America
  • 10.5. Asia Pacific
    • 10.5.1. Introduction
    • 10.5.2. Key Region-Specific Dynamics
    • 10.5.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.5.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 10.5.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel
    • 10.5.6. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Country
      • 10.5.6.1. China
      • 10.5.6.2. India
      • 10.5.6.3. Japan
      • 10.5.6.4. Australia
      • 10.5.6.5. Rest of Asia Pacific
  • 10.6. Middle East and Africa
    • 10.6.1. Introduction
    • 10.6.2. Key Region-Specific Dynamics
    • 10.6.3. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Drug Class
    • 10.6.4. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Indication
    • 10.6.5. Market Size Analysis, and Y-o-Y Growth Analysis (%), By Distribution Channel

11. Global Immunosuppressants Drugs Market - Competitive Landscape

  • 11.1. Key Developments and Strategies
  • 11.2. Company Share Analysis
  • 11.3. Product Benchmarking
  • 11.4. List of key companies to watch
  • 11.5. List of the company with disruptive technology
  • 11.6. List of start-up companies

12. Global Immunosuppressants Drugs Market- Company Profiles

  • 12.1. Pfizer Inc*
    • 12.1.1. Company Overview
    • 12.1.2. Product Portfolio and Description
    • 12.1.3. Key Highlights
    • 12.1.4. Financial Overview
  • 12.2. Astellas Pharma, Inc
  • 12.3. Sanofi (Genzyme)
  • 12.4. Bristol-Myers Squibb Company
  • 12.5. Novartis AG
  • 12.6. F. Hoffmann-La Roche Ltd
  • 12.7. GlaxoSmithKline Plc
  • 12.8. Allergan Plc
  • 12.9. Accord Healthcare Ltd
  • 12.10. Mylan Laboratories, Inc

LIST NOT EXHAUSTIVE

13. Global Immunosuppressants Drugs Market - DataM

  • 13.1. Appendix
  • 13.2. About Us and Services
  • 13.3. Contact Us